Almirall, S.A. (0O9B.IL)

8.15 -0.01 (-0.15%) At close: 05:57PM BST

Almirall, S.A.

Ronda Del General Miter, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,876

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Carlos Gallardo Piqué	CEO & Chairman	50k	N/A	1972
Mr. Michael McClellan	Exec. VP of Fin., CFO & Member of Management Board	N/A	N/A	1972
Mr. Eloi Crespo Cervera	Sr. VP of Industrial Operations & Member of Management Board	N/A	N/A	N/A
Mr. Jordi Sabé Richer	Sr. VP of Corp. Devel. & Member of Management Board	N/A	N/A	N/A
Mr. Esteve Conesa Panicot	Sr. VP of HR & Member of Management Board	N/A	N/A	N/A
Dr. Volker Koscielny	Chief Medical Officer & Member of Management Board	N/A	N/A	N/A
Mr. Pablo Alvarez	Member of Management Board, Pres of Almirall US & GM of Almirall US	N/A	N/A	N/A
Dr. Karl Ziegelbauer	Exec. VP of R&D, CSO and Member of Management Board	N/A	N/A	N/A
Mr. Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	N/A	N/A	N/A
Ms. Isabel Gomes	Gen. Counsel & Member of Management Board	N/A	N/A	N/A

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Corporate governance

Almirall, S.A.’s ISS governance QualityScore as of 1 October 2023 is 4. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.